Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)
Information source: Department of Veterans Affairs
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Post-Traumatic Stress Disorder
Intervention: guanfacine (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Department of Veterans Affairs
Summary
This is a double-blind, placebo-controlled, randomized study lasting 8 weeks. Purpose of the
study is two-fold: first, to use a pharmacological agent to treat symptoms of PTSD, and
second, to explore neurobiological mechanisms of action of guanfacine.
Clinical Details
Official title: Guanfacine for the Treatment of PTSD
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Detailed description:
Subject population is comprised of 100 persons with PTSD. 50 patients will receive
guanfacine and 50 patients will receive a placebo. Guanfacine is prescribed at 1 mg/day and
may be increased to 2 mg/day. Samples of plasma MHPG will be collected weekly. Clinical
ratings of PTSD anxiety and depression, as well as vital signs, will be assessed weekly.
Repeated measures analysis of variance will assess significance of main effect of drug, time,
and drug by time.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
- Males and females, age 18-65
- Diagnosis of PTSD from combat or civilian trauma
- No major medical problems such as diabetes, cardiovascular disease
- Taking no psychiatric medication, or taking only one SSRI antidepressant
Locations and Contacts
VA Connecticut Healthcare System, West Haven, Connecticut 06516, United States
Additional Information
Starting date: November 1999
Ending date: October 2002
Last updated: June 23, 2005
|
